Is Beta Drugs a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Beta Drugs Ltd is a good quality company .

Is Beta Drugs undervalued or overvalued?

The key valuation ratios of Beta Drugs Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Beta Drugs share price return in the past 10 years?

Data is not available for this company

Is Beta Drugs a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Beta Drugs Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

Beta Drugs Ltd - Stock Valuation and Financial Performance

Name: Beta Drugs
Brand: Beta Drugs

BSE: 0 | NSE: BETA | Pharmaceuticals & Drugs | Small Cap

Place order

BSE Share Price
Not Listed

10 Year X-Ray of Beta Drugs:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	-2.6%	21.9%	48.9%	28.6%	18.4%	16.9%	15.9%	26.9%	27.9%	27.3%	-
Value Creation Index ⓘ	-1.2	0.6	2.5	1.1	0.3	0.2	0.1	0.9	1.0	1.0	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	0.3	26.4	41.7	50.6	58.1	65.3	79.5	125	158	198	198
Sales YoY Gr.	-	10,046.2%	57.9%	21.4%	14.8%	12.5%	21.7%	57.1%	26.5%	25.2%	-
Adj EPS ⓘ	-0.2	1.9	7.8	8.5	9.2	7.4	7.3	14.8	19.6	22.8	22.8
YoY Gr.	-	NA	309.5%	9.1%	8.6%	-20.2%	-1.2%	103.9%	32.1%	16.6%	-
BVPS (₹) ⓘ	10.6	21.8	10.2	38	46.9	58.7	66	80.6	100.1	120.7	120.7
Adj Net Profit ⓘ	-0.1	1.1	4.6	7.4	8	7.1	7	14.3	18.8	21.9	22
Cash Flow from Ops. ⓘ	1.4	-0.4	4.7	17.1	7.7	6.1	11.6	18.8	10.2	21.2	-
Debt/CF from Ops. ⓘ	3.4	-22.5	1.7	0.5	1	1.5	0.5	0.4	0.6	0.3	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	109%	27.8%	35.5%	25.2%
Adj EPS ⓘ	NA	19.9%	46.4%	16.6%
BVPSⓘ	31.1%	20.8%	22.3%	20.5%
Share Price	-	91.6%	59.7%	68%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	-18.3	69.4	112	37.7	21.7	14.6	11.7	20.2	21.7	20.7	18.9
Op. Profit Mgn % ⓘ	2.5	11.4	18.7	20.4	18.4	18	19.3	20.2	19.8	17	NAN
Net Profit Mgn % ⓘ	-43.5	4.3	11.1	14.5	13.7	10.8	8.8	11.4	11.9	11.1	11.1
Debt to Equity ⓘ	4.5	3.8	1.4	0.2	0.2	0.2	0.1	0.1	0.1	0.1	-
Working Cap Days ⓘ	1,675	65	99	138	180	211	196	149	157	170	0
Cash Conv. Cycle ⓘ	354	2	26	47	63	73	66	41	49	51	0

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 35.49%

Net Profit is growing at healthy rate in last 3 years 46.42%

Return on Equity has declined versus last 3 years average to 18.90%

Sales growth is not so good in last 4 quarters at 0.00%

Latest Financials - Beta Drugs Ltd.

	Standalone	Consolidated
TTM EPS (₹)	22.8	37.9
TTM Sales (₹ Cr.)	198	296
BVPS (₹.) ⓘ	120.7	163.4
Reserves (₹ Cr.) ⓘ	106	148
P/BV ⓘ	16.70	12.33
PE ⓘ	88.31	53.17

From the Market
52 Week Low / High (₹)	0.00 / 0.00
All Time Low / High (₹)	- / -
Market Cap (₹ Cr.)	1,937
Equity (₹ Cr.)	9.6
Face Value (₹)	10
Industry PE ⓘ	43

Management X-Ray of Beta Drugs:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Beta Drugs

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Beta Drugs

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	0	26	42	51	58	65	79	125	158	198
Operating Expenses ⓘ	0	23	34	41	48	54	64	100	127	164
Manufacturing Costs	0	0	1	6	7	8	9	12	15	17
Material Costs	0	15	24	27	30	35	43	71	83	112
Employee Cost	0	3	4	1	2	4	5	7	10	11
Other Costs ⓘ	0	5	5	6	8	7	7	10	18	24
Operating Profit ⓘ	0	3	7	9	10	12	15	25	31	34
Operating Profit Margin (%)	2.5%	11.4%	17.5%	18.7%	17.8%	18.0%	19.3%	20.2%	19.8%	17.0%
Other Income ⓘ	0	0	0	0	0	0	1	1	1	2
Interest ⓘ	0	1	1	1	1	1	1	0	1	1
Depreciation ⓘ	0	1	1	2	2	3	5	5	6	5
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	0	1	5	7	7	9	10	20	25	29
Tax ⓘ	0	0	1	0	0	2	3	6	6	8
Profit After Tax	0	1	4	7	8	7	7	14	19	22
PAT Margin (%)	-43.5%	4.3%	10.2%	13.4%	13.3%	10.9%	8.8%	11.4%	11.9%	11.1%
Adjusted EPS (₹)	-0.2	1.9	7.2	7.8	8.9	7.4	7.3	14.8	19.6	22.8
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	1	2	6	33	41	56	63	77	96	116
Share Capital ⓘ	1	1	1	9	9	10	10	10	10	10
Reserves ⓘ	0	1	5	24	32	47	54	68	87	106
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	4	8	8	6	6	7	4	5	4	4
Long Term Debt	4	4	4	3	5	3	3	5	4	4
Short Term Debt	0	4	4	4	1	4	1	0	0	0
Trade Payables	2	4	7	6	10	9	13	20	23	36
Others Liabilities ⓘ	0	1	3	4	9	10	8	12	14	20
Total Liabilities ⓘ	8	15	23	50	66	83	89	115	137	175
Fixed Assets
Gross Block	1	9	11	18	19	42	43	54	60	65
Accumulated Depreciation	1	2	3	5	7	10	15	20	25	29
Net Fixed Assetsⓘ	1	7	8	13	12	32	28	34	35	36
CWIP ⓘ	6	0	0	1	15	0	2	0	0	0
Investmentsⓘ	0	0	0	0	2	6	7	7	7	6
Inventories	1	3	2	3	6	6	8	8	14	22
Trade Receivables	0	4	11	14	17	21	21	31	44	50
Cash Equivalents	0	0	0	12	3	4	8	16	18	27
Others Assetsⓘ	0	0	2	6	10	14	15	19	21	33
Total Assets ⓘ	8	15	23	50	66	83	89	115	137	175

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	1	0	5	17	8	6	12	19	10	21
PBT ⓘ	0	1	5	7	7	9	10	20	25	29
Adjustment ⓘ	0	2	2	15	2	2	4	3	0	-6
Changes in Working Capital ⓘ	1	-3	-3	-5	-1	-4	-2	-5	-15	-2
Tax Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Cash Flow From Investing Activity ⓘ	-6	-2	-2	-11	-16	-14	-3	-13	-6	-11
Capex	-6	-2	-2	-8	-15	-8	-3	-10	-7	-6
Net Investments	0	0	0	0	-2	-5	0	0	0	1
Others ⓘ	0	0	0	-3	0	-2	1	-3	1	-5
Cash Flow From Financing Activityⓘ	4	3	-3	5	-1	9	-4	1	-2	-1
Net Proceeds from Shares ⓘ	1	0	0	8	0	9	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	-1	-1	3	-1	0	2	-1	0
Interest Paid ⓘ	0	-1	-1	-1	-1	-1	-1	0	-1	-1
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	3	3	-1	0	-2	3	-3	-1	0	0
Net Cash Flow ⓘ	0	0	0	12	-9	1	4	7	2	9

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	-18.28	69.39	103.22	34.73	21	14.63	11.64	20.23	21.66	20.67
ROCE (%)	-2.61	21.92	48.91	28.63	18.42	16.85	15.91	26.91	27.93	27.27
Asset Turnover Ratio	0.06	2.27	2.17	1.39	1.01	0.88	0.92	1.23	1.26	1.27
PAT to CFO Conversion(x)	N/A	0	1.25	2.43	1	0.86	1.71	1.36	0.53	0.95
Working Capital Days
Receivable Days	256	31	65	90	100	107	96	76	87	87
Inventory Days	1,093	29	23	19	29	35	32	24	26	33
Payable Days	2,828	75	85	88	98	102	95	85	94	96

Beta Drugs Ltd Stock News

Beta Drugs Ltd FAQs

What is the share price of Beta Drugs?

Company share prices are keep on changing according to the market conditions. The closing price of Beta Drugs on 01-Jan-1970 05:30 is ₹0.00.

What is the market cap of Beta Drugs?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Beta Drugs stood at ₹1,937.2.